DaVita (NYSE:DVA) Price Target Cut to $128.00 by Analysts at Truist Financial

DaVita (NYSE:DVA) had its price target lowered by Truist Financial from $140.00 to $128.00 in a research note issued to investors on Monday,MarketScreener reports. The firm presently has a “hold” rating on the stock. Truist Financial’s target price would suggest a potential upside of 11.80% from the stock’s current price.

A number of other research firms have also commented on DVA. UBS Group reissued a “buy” rating on shares of DaVita in a research report on Monday, December 15th. Zacks Research upgraded DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Barclays dropped their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday, October 30th. Bank of America reduced their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research note on Wednesday, September 10th. Finally, Cowen reiterated a “hold” rating on shares of DaVita in a report on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $145.60.

DaVita Price Performance

Shares of DVA stock opened at $114.50 on Monday. The firm has a market cap of $8.08 billion, a P/E ratio of 11.68, a PEG ratio of 0.70 and a beta of 0.99. DaVita has a 1-year low of $112.54 and a 1-year high of $179.60. The firm’s 50-day simple moving average is $118.54 and its 200-day simple moving average is $129.64.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.DaVita’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Analysts expect that DaVita will post 10.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC increased its stake in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the last quarter. Petrus Trust Company LTA raised its position in DaVita by 12.7% during the 1st quarter. Petrus Trust Company LTA now owns 2,047 shares of the company’s stock valued at $313,000 after purchasing an additional 230 shares during the last quarter. UniSuper Management Pty Ltd increased its position in DaVita by 1.2% during the 1st quarter. UniSuper Management Pty Ltd now owns 11,645 shares of the company’s stock valued at $1,781,000 after purchasing an additional 139 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in DaVita in the first quarter worth about $364,000. Finally, Goldman Sachs Group Inc. lifted its position in DaVita by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares during the period. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.